Last reviewed · How we verify
GD2 CAR modified Tri-virus specific cytotoxic t-cells
GD2 CAR modified Tri-virus specific cytotoxic t-cells is a Biologic drug developed by Children's Mercy Hospital Kansas City. It is currently in Phase 1 development.
At a glance
| Generic name | GD2 CAR modified Tri-virus specific cytotoxic t-cells |
|---|---|
| Sponsor | Children's Mercy Hospital Kansas City |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GD2 CAR modified Tri-virus specific cytotoxic t-cells CI brief — competitive landscape report
- GD2 CAR modified Tri-virus specific cytotoxic t-cells updates RSS · CI watch RSS
- Children's Mercy Hospital Kansas City portfolio CI
Frequently asked questions about GD2 CAR modified Tri-virus specific cytotoxic t-cells
What is GD2 CAR modified Tri-virus specific cytotoxic t-cells?
GD2 CAR modified Tri-virus specific cytotoxic t-cells is a Biologic drug developed by Children's Mercy Hospital Kansas City.
Who makes GD2 CAR modified Tri-virus specific cytotoxic t-cells?
GD2 CAR modified Tri-virus specific cytotoxic t-cells is developed by Children's Mercy Hospital Kansas City (see full Children's Mercy Hospital Kansas City pipeline at /company/children-s-mercy-hospital-kansas-city).
What development phase is GD2 CAR modified Tri-virus specific cytotoxic t-cells in?
GD2 CAR modified Tri-virus specific cytotoxic t-cells is in Phase 1.